Article
Nasal anti-CD3 mAb (Foralumab) dampens CD3+ T effector function and decreases NKG7 in COVID-19 through a mechanism involving GIMAP-7 and TGFb1
2022-10-13
Abstract excerpt
<title>Abstract</title> <p>T cells are present in early stages of the SARS-CoV-2 infection and play a major role in disease outcome and long-lasting immunity. Nasal administration of a fully humanized anti-CD3 monoclonal antibody (Foralumab) reduced lung inflammation as well as serum IL-6 and C-reactive protein in moderate cases of COVID-19. Using RNA-sequencing and serum proteomics, we investigated the immune ch...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 4d6849b8-4c56-508b-973e-2e027e7ff1bd
- DOI
- 10.21203/rs.3.rs-2061549/v1
